The pace of innovation in cancer care and screening is accelerating. In the past several years, medical innovations in cancer care have been accelerating, including advances in immunotherapy, targeted treatments, and genomics. Despite this, cancer mortality remains stubbornly high and extremely costly. New approaches to earlier and more effective diagnosis may lead to greater precision about who should get which treatment. For instance, liquid biopsies have already become established in guiding therapy selection for established cancer patients but will MCED (multicancer early detection) tests replace mammograms, colonoscopy and PSA? Finally AI is being incorporated into every layer of cancer care—will it change the way we find cancer in the first place? This panel of experts will provide insight into how we are incorporating innovations into our healthcare systems and what the future of cancer screening and care looks like.

Moderator

William K. Oh

Chief Medical Officer, Prostate Cancer Foundation

Speakers

Tomasz Beer

Chief Medical Officer, Multi-Cancer Early Detection, Exact Sciences

Alasdair Milton

Principal, Healthcare and Life Sciences, KPMG

Rachel B. Ramoni

Chief Research and Development Officer, Office of Discovery, Education, and Affiliate Networks, US Department of Veterans Affairs